Orforglipron and Heart Events in People With Heart Artery Disease or Chronic Kidney Disease
Tests orforglipron against placebo for heart problems in adults with artery or kidney disease.
Plain-language title generated from the registry record
Registry title: A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Key facts
- Where
- 'S-Hertogenbosch, Almere, Amersfoort, Amsterdam, Apeldoorn, Arnhem, Dirksland, Doetinchem, Dordrecht, Eindhoven, Gouda, Groningen, Heerenveen, Leeuwarden, Leiderdorp, Nijmegen, Roosendaal, Schiedam, Utrecht, Veldhoven, and Venlo, NetherlandsSee the 23 sites
- Phase
- Phase 3
Where in Netherlands
- Jeroen Bosch Ziekenhuis Stichting'S-Hertogenbosch, NetherlandsTaking people
- EB FlevoResearch B.V.Almere, NetherlandsTaking people
- Meander Medisch CentrumAmersfoort, NetherlandsTaking people
- Academisch Medisch CentrumAmsterdam, NetherlandsTaking people
- Stichting OLVGAmsterdam, NetherlandsTaking people
- Gelre HospitalsApeldoorn, NetherlandsTaking people
- Rijnstate Ziekenhuis StichtingArnhem, NetherlandsTaking people
- Het Van Weel-Bethesda ZiekenhuisDirksland, NetherlandsTaking people
- Slingeland ZiekenhuisDoetinchem, NetherlandsTaking people
- Albert Schweitzer ZiekenhuisDordrecht, NetherlandsTaking people
- Catharina Ziekenhuis StichtingEindhoven, NetherlandsTaking people
- Groene Hart ZiekenhuisGouda, NetherlandsTaking people
- Stichting Martini ZiekenhuisGroningen, NetherlandsTaking people
- Frisius MCHeerenveen, NetherlandsTaking people
- Frisius MCLeeuwarden, NetherlandsTaking people
- Alrijne Zorggroep StichtingLeiderdorp, NetherlandsTaking people
- Radboud universitair medisch centrum StichtingNijmegen, NetherlandsTaking people
- Bravis ZiekenhuisRoosendaal, NetherlandsTaking people
- Sint Franciscus Vlietland Groep StichtingSchiedam, NetherlandsTaking people
- Diakonessenhuis StichtingUtrecht, NetherlandsTaking people
- Universitair Medisch Centrum UtrechtUtrecht, NetherlandsTaking people
- Maxima Medisch CentrumVeldhoven, NetherlandsTaking people
- Stichting Viecuri Medisch Centrum voor Noord-LimburgVenlo, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07241390EU 2025-523123-22-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.Read full original descriptionShow less
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Inclusion: Have established ASCVD and/or CKD.
Exclusion: Have had a major heart condition within 60 days prior to screening; Have type 1 diabetes; Have New York Heart Association Functional Classification Class IV heart failure.